PLRX · Pliant Therapeutics Inc
-
-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US7291391057 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 1.28 |
|---|---|
| Market Cap | 80M |
| PE Ratio | None |
| Target Price | 2.6667 |
| Dividend Yield | None |
ABOUT
Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Learn More